---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-299797"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2022-12-07T23:59:59+00:00"
generated_at: "2026-06-21T08:15:30.085956+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vor Bio reports initial clinical proof-of-concept for trem-cel; first AML patient engrafts normally

## Summary
- First patient received trem-cel dose of 7.6x10^6 CD34+ cells/kg with 88% CD33 editing efficiency.
- Neutrophil engraftment at 10 days, platelet recovery Day 22; >90% of PBMCs CD33-negative, 100% donor chimerism.
- No infusion reactions or treatment-related adverse events observed post-transplant.
- Mylotarg 0.5 mg/m^2 tolerated with no neutropenia or liver enzyme changes through Day 20.
- Trial continues enrolling; additional data expected in 2023; conference call Dec 7 at 8am ET.

## SEC filing metadata
- accession: 0001193125-22-299797
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2022-12-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312522299797/0001193125-22-299797-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312522299797/d431519d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-299797
- JSON: https://secwatch.observer/filing/0001193125-22-299797.json
- Plain text: https://secwatch.observer/filing/0001193125-22-299797.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.